| Literature DB >> 28103733 |
Juan Carlos Ramos Gonçalves1,2, Danilo Andrade de Meneses2, Aliny Pereira de Vasconcelos2, Celyane Alves Piauilino1, Fernanda Regina de Castro Almeida1, Edoardo Marco Napoli3, Giuseppe Ruberto3, Demetrius Antônio Machado de Araújo2.
Abstract
CONTEXT: The essential oil (EO) from Thymus capitatus Hoff. et Link. (Lamiaceae) has been traditionally used for its medicinal properties, such as anti-inflammatory, analgesic, antioxidant and antimicrobial properties.Entities:
Keywords: Pain; action potential; glutamate
Mesh:
Substances:
Year: 2017 PMID: 28103733 PMCID: PMC6130693 DOI: 10.1080/13880209.2017.1279672
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.503
Chemical composition of T. capitatus essential oil (EO).
| # | KI | Compound | Area |
|---|---|---|---|
| 1 | 778 | 2-Methyl-butanoic acid methyl ester | 0.1 |
| 2 | 932 | α-Thujene | 0.7 |
| 3 | 939 | α-Pinene | 0.6 |
| 4 | 954 | Camphene | 0.2 |
| 5 | 982 | β-Pinene | 0.4 |
| 6 | 993 | β-Myrcene | 1.7 |
| 7 | 1008 | α-Phellandrene | 0.2 |
| 8 | 1015 | 0.1 | |
| 9 | 1021 | α-Terpinene | 1.2 |
| 10 | 1033 | 4.4 | |
| 11 | 1035 | Limonene | 0.4 |
| 12 | 1052 | 0.1 | |
| 13 | 1063 | γ-Terpinene | 3.7 |
| 14 | 1072 | Sabinene Hydrate | 0.2 |
| 15 | 1091 | α-Terpinolene | 0.2 |
| 16 | 1100 | Linalool | 0.9 |
| 17 | 1126 | α-Campholenal | 0.1 |
| 18 | 1172 | Borneol | 0.4 |
| 19 | 1181 | Terpinen-4-ol | 0.8 |
| 20 | 1193 | α-Terpineol | 0.1 |
| 21 | 1248 | Nerol | 0.1 |
| 22 | 1255 | Neral | 0.1 |
| 23 | 1264 | Carvone | 0.1 |
| 24 | 1273 | Geranial | 0.1 |
| 25 | 1290 | Thymol | 0.3 |
| 26 | 1313 | Carvacrol | 79.9 |
| 27 | 1362 | Thymol acetate | 0.1 |
| 28 | 1425 | Caryophyllene | 2.3 |
| 29 | 1446 | Aromadendrene | 0.1 |
| 30 | 1460 | α-Humulene | 0.1 |
| 31 | 1511 | β-Bisabol | 0.2 |
| 32 | 1545 | α-Cadinene | 0.2 |
| 33 | 1589 | Caryophyllene Oxide | 0.2 |
| Monoterpene hydrocarbons | 13.7 | ||
| Oxygenated monoterpenes | 83.0 | ||
| Sesquiterpenes | 3.1 | ||
| Others | 0.1 | ||
KI: Kovat’s indices; RT: retention time.
Retention index (KI) relative to standard mixture of n-alkanes on SPB-5 column.
The numbering refers to elution order, and values (relative peak area percent) represent averages of 3 determinations.
Figure 1.Antinociceptive effect of T. capitatus EO in mice. The T. capitatus EO was administered in mice orally (3–12 mg/kg) 1 h before initiating the glutamate-induced nociception method. Control animals were treated with vehicle alone. Morphine (5 mg/kg) was used as a positive control. Values are expressed as mean ± S.E.M, n = 8. *p < 0.05, ***p < 0.001 vs. control (ANOVA followed by Dunnet’s test).
Figure 2.T. capitatus EO reversibly blocks the peripheral nerve excitability. (A) Representative CAP recordings obtained by the single sucrose gap technique after 5, 15 and 30 min of T. capitatus EO (500 μg/mL) incubation. After drug incubation, the nerve was washed out with the physiological solution for 30 min. Control records were obtained when sciatic nerves were submitted to the physiological solution only. Stimulation parameters were 6–10 V/0.1 ms. (B) Time- and concentration-dependent effects of T. capitatus EO (1–500 μg/mL) on CAP amplitude (V) during 30 min incubation followed by nerve washout (30 min). Values are expressed as mean ± S.E.M, n = 4. *p < 0.05; **p < 0.01; ***p < 0.001 vs. control (Student’s t-test).
Figure 3.Effects of T. capitatus on the depolarization and repolarization phases of the CAP. T. capitatus EO (TC, 100 μg/mL) was incubated in the rat sciatic nerve for 30 min followed by drug washout out with the physiological solution. The CAP parameters like (A) the depolarization velocity (DV), and (B) the time constant of repolarization (τ), were quantified and compared to control. Values are expressed as mean ± S.E.M, n = 4. *p < 0.05 vs. control (Student’s t-test).